K092169

DEC 16 2009

510(k) Summary

Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, address, contact

Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46250
317-521-3208

Contact Person: Kelly French

Date Prepared: July 15, 2009

Device Name

Proprietary name: Elecsys proBNP II CalCheck 5

Common name: proBNP II CalCheck 5

Classification name: Single (specified) analyte controls (assayed and unassayed)

Predicate device

The Elecsys proBNP II CalCheck 5 is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys proBNP II CalCheck (K080147).

Device Description

The Elecsys proBNP II CalCheck 5 is a lyophilized product consisting of NT-proBNP (1-76) amide, human serum and a potassium phosphate buffered matrix. During manufacture, the analytes are spiked into the matrix at the desired concentration levels.

Intended use

The Elecsys proBNP II CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys proBNP II reagent on the indicated Elecsys and **cobas e** immunoassay analyzers.

Continued on next page

Comparison Table

The table below compares Elecsys proBNP II CalCheck 5 with the predicate device, Elecsys proBNP II Calcheck (K080147).

Characteristic	Elecsys proBNP II CalCheck (K080147)	Elecsys proBNP II CalCheck 5
Intended Use	For use in the verification of the calibration established by the Elecsys proBNP II reagent on the Elecsys and cobas e immunoassay analyzers.	The Elecsys proBNP II CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys proBNP II reagent on the indicated Elecsys and **cobas e** immunoassay analyzers.
Levels	Three	Five
Format	Lyophilized	Same
Handling	Reconstitute with exactly 1.0 mL distilled or deionized water and allow standing closed for 15 minutes, then mixing gently.	Same
Stability	Unopened: • Store at 2-8°C until expiration date Reconstituted: • 20 – 25 °C : 4 hrs	Same
Matrix	Human serum	Same
Buffer	Potassium phosphate buffer	Same

Performance Characteristics

The Elecsys proBNP II CalCheck 5 was evaluated for value assignment and stability.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Roche Diagnostics
Roche Professional Diagnostics
c/o Ms. Kelly French
Regulatory Affairs Consultant
9115 Hague Road
P.O. Box 50416
Indianapolis, IN 46250-0416

Food and Drug Administration
10903 New Hampshire Avenue
Document Mail Center – WO66-0609
Silver Spring, MD 20993-0002

DEC 16 2009

Re: k092169
Trade Name: Elecsys proBNP II CalCheck 5
Regulation Number: 21 CFR §862.1660
Regulation Name: Quality Control Material (assayed and unassayed)
Regulatory Class: Class I, reserved
Product Codes: JJX
Dated: December 1, 2009
Received: December 2, 2009

Dear Ms. French:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Courtney C. Harper, Ph.D.
Director
Division of Chemistry and Toxicology
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): k092169

Device Name: Elecsys proBNP II CalCheck 5

Indications For Use:

The Elecsys proBNP II CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys proBNP II reagent on the indicated Elecsys and cobas e immunoassay analyzers.

Prescription Use __X_____ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Carol C. Benson

Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety
510(k) K092169